Envista (NYSE:NVST) Given New $21.00 Price Target at UBS Group

Envista (NYSE:NVST - Get Free Report) had its price target lowered by stock analysts at UBS Group from $23.00 to $21.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. UBS Group's price objective suggests a potential upside of 28.72% from the stock's previous close.

A number of other analysts have also issued reports on the stock. Piper Sandler lifted their price target on shares of Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Wells Fargo & Company boosted their target price on shares of Envista from $20.00 to $21.00 and gave the company an "equal weight" rating in a research note on Thursday, February 6th. Needham & Company LLC reiterated a "hold" rating on shares of Envista in a research note on Thursday, March 6th. Morgan Stanley lowered their target price on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $20.18.

Remove Ads

Envista Stock Up 0.4 %

Shares of NYSE:NVST traded up $0.07 during midday trading on Monday, reaching $16.32. The company had a trading volume of 1,292,289 shares, compared to its average volume of 2,283,139. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The stock's fifty day moving average price is $20.04 and its 200-day moving average price is $19.64. The stock has a market capitalization of $2.81 billion, a P/E ratio of -2.51, a PEG ratio of 1.27 and a beta of 1.33. Envista has a one year low of $15.15 and a one year high of $23.00.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts expect that Envista will post 1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Envista

Institutional investors have recently bought and sold shares of the stock. Pacer Advisors Inc. lifted its holdings in Envista by 22.2% in the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock worth $69,749,000 after purchasing an additional 642,401 shares during the period. Diamond Hill Capital Management Inc. lifted its holdings in Envista by 8.1% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company's stock worth $26,394,000 after purchasing an additional 100,360 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Envista in the fourth quarter worth about $53,000. Lecap Asset Management Ltd. acquired a new stake in Envista in the 4th quarter valued at about $281,000. Finally, Hotchkis & Wiley Capital Management LLC acquired a new stake in Envista in the 3rd quarter valued at about $14,965,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.